Neutralization of human immunodeficiency virus type 1 by complement occurs by viral lysis.
The ability of complement to inactivate human immunodeficiency virus (HIV) in the presence of specific antibody was evaluated. HIV was treated with complement and/or antibody, and then its titer was determined on the CD4+ H9 cell line. While complement alone had no effect on the HIV titer, complement plus subneutralizing levels of antibody resulted in titer reductions. Complement sources deficient in membrane attack component C5 or C8 did not inactivate antibody-treated HIV, suggesting that neutralization occurred via lysis. This possibility was investigated by assessing release of reverse transcriptase (RT) from the virion. Antibody plus complement, but neither reagent alone, released RT from HIV in a dose-dependent manner. Release of RT did not occur with C5- or C8-deficient sera, also indicating a requirement for membrane attack components. These studies show that complement can neutralize HIV via the classical complement pathway and that this neutralization occurs via C5b-9-mediated viral lysis. Thus, complement may play a major role in resistance to disease by lysing HIV and preventing infection of Fc- and complement receptor-positive cells, as well as CD4+ cells.
Department of Immunology/Microbiology, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612.
G T
GT
Spear
B L
BL
Sullivan
A L
AL
Landay
T F
TF
Lint
D000917:Antibody Formation; D000920:Antibody-Dependent Cell Cytotoxicity; D002460:Cell Line; D003165:Complement System Proteins / Q000276:immunology*; D015497:HIV-1 / Q000201:enzymology / Q000276:immunology*; D006801:Humans; D008242:Lysogeny; D009500:Neutralization Tests; D012194:RNA-Directed DNA Polymerase / Q000032:analysis
D003165:Complement System Proteins; D012194:RNA-Directed DNA Polymerase